asenapine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
psychoactive 4115 65576-45-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • Org-5222
  • Org 5222
  • asenapine
  • saphris
  • asenapine maleate
  • sycrest
  • Molecular weight: 285.77
  • Formula: C17H16ClNO
  • CLOGP: 4.28
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 12.47
  • ALOGS: -3.96
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.71 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 23 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 12.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Aug. 13, 2009 FDA FOREST LABS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anosognosia 867.76 33.63 169 8227 2065 50594663
Blood prolactin abnormal 859.95 33.63 167 8229 2008 50594720
Disturbance in social behaviour 818.24 33.63 168 8228 2726 50594002
Sexual dysfunction 790.91 33.63 167 8229 3125 50593603
Dystonia 727.51 33.63 200 8196 11726 50585002
Metabolic disorder 706.89 33.63 166 8230 5120 50591608
Personality change 675.30 33.63 162 8234 5483 50591245
Sedation 662.81 33.63 232 8164 30378 50566350
Dyskinesia 583.23 33.63 206 8190 27655 50569073
Inappropriate schedule of product administration 550.90 33.63 258 8138 71573 50525155
Underdose 439.58 33.63 154 8242 20124 50576604
Hypoaesthesia oral 430.59 33.63 130 8266 10598 50586130
Suicide attempt 412.16 33.63 191 8205 51541 50545187
Blood glucose increased 354.00 33.63 191 8205 71133 50525595
Incorrect route of product administration 286.49 33.63 110 8286 18556 50578172
Akathisia 259.68 33.63 83 8313 8146 50588582
Insurance issue 170.27 33.63 46 8350 2502 50594226
Dysgeusia 133.21 33.63 82 8314 38834 50557894
Swollen tongue 117.96 33.63 68 8328 28562 50568166
Weight increased 92.97 33.63 139 8257 201752 50394976
Mania 82.61 33.63 39 8357 10877 50585851
Tooth discolouration 78.59 33.63 20 8376 859 50595869
Tardive dyskinesia 77.43 33.63 33 8363 7246 50589482
Extrapyramidal disorder 70.94 33.63 36 8360 11734 50584994
Adverse drug reaction 67.80 33.63 63 8333 55159 50541569
Suicidal ideation 63.81 33.63 61 8335 55324 50541404
Condition aggravated 59.14 33.63 143 8253 296915 50299813
Restless legs syndrome 58.19 33.63 35 8361 15862 50580866
Oral discomfort 52.66 33.63 26 8370 7991 50588737
Oropharyngeal blistering 51.35 33.63 14 8382 787 50595941
Diarrhoea 49.58 33.63 18 8378 588458 50008270
Tongue blistering 48.21 33.63 15 8381 1343 50595385
Somnolence 44.98 33.63 87 8309 154898 50441830
Fatigue 42.95 33.63 33 8363 707568 49889160
Agitation 37.08 33.63 45 8351 53339 50543389
Completed suicide 35.78 33.63 72 8324 131817 50464911
Personality change due to a general medical condition 35.26 33.63 7 8389 94 50596634
Arthralgia 34.29 33.63 15 8381 438687 50158041
Pain 33.81 33.63 28 8368 578875 50017853

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Akathisia 369.02 35.32 106 5270 6636 29562515
Suicide attempt 358.70 35.32 157 5219 33953 29535198
Anosognosia 318.60 35.32 63 5313 755 29568396
Sedation 317.07 35.32 119 5257 17286 29551865
Blood prolactin abnormal 291.55 35.32 59 5317 801 29568350
Therapeutic product effect variable 271.71 35.32 64 5312 1813 29567338
Antipsychotic drug level below therapeutic 268.50 35.32 64 5312 1910 29567241
Disturbance in social behaviour 256.69 35.32 60 5316 1642 29567509
Disinhibition 255.74 35.32 65 5311 2542 29566609
Dystonia 254.21 35.32 87 5289 9662 29559489
Obsessive-compulsive disorder 241.56 35.32 70 5306 4506 29564645
Increased appetite 230.48 35.32 72 5304 5992 29563159
Euphoric mood 216.12 35.32 65 5311 4760 29564391
Sexual dysfunction 208.32 35.32 66 5310 5748 29563403
Metabolic disorder 206.05 35.32 59 5317 3636 29565515
Inappropriate schedule of product administration 180.98 35.32 108 5268 44364 29524787
Dyskinesia 180.61 35.32 83 5293 19978 29549173
Personality change 151.12 35.32 49 5327 4589 29564562
Emotional poverty 128.62 35.32 27 5349 442 29568709
Weight increased 119.73 35.32 104 5272 76563 29492588
Hypoaesthesia oral 114.56 35.32 37 5339 3419 29565732
Underdose 112.69 35.32 51 5325 11818 29557333
Therapeutic product effect incomplete 104.21 35.32 73 5303 39232 29529919
Incorrect route of product administration 91.84 35.32 43 5333 10758 29558393
Dyslipidaemia 90.73 35.32 36 5340 6025 29563126
Extrapyramidal disorder 85.59 35.32 41 5335 10790 29558361
Leukaemia 83.83 35.32 30 5346 3780 29565371
Blood glucose increased 82.00 35.32 75 5301 58909 29510242
Drug ineffective 80.50 35.32 192 5184 362978 29206173
Prescribed overdose 78.27 35.32 36 5340 8647 29560504
Obesity 76.91 35.32 37 5339 9826 29559325
Leukopenia 72.46 35.32 68 5308 55135 29514016
Mania 63.03 35.32 31 5345 8632 29560519
Dysgeusia 59.76 35.32 42 5334 22632 29546519
Swollen tongue 58.24 35.32 33 5343 12233 29556918
Sedation complication 51.92 35.32 16 5360 1266 29567885
Suicidal ideation 47.89 35.32 44 5332 34672 29534479
Toxicity to various agents 45 35.32 98 5278 173563 29395588
Cogwheel rigidity 44.02 35.32 14 5362 1229 29567922
Head titubation 42.48 35.32 10 5366 281 29568870
Schizoaffective disorder 41.58 35.32 13 5363 1079 29568072
Insurance issue 39.14 35.32 12 5364 933 29568218

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anosognosia 1114.18 32.08 213 9550 2592 64486377
Blood prolactin abnormal 1076.04 32.08 206 9557 2526 64486443
Disturbance in social behaviour 1009.45 32.08 207 9556 3680 64485289
Sexual dysfunction 936.67 32.08 213 9550 6258 64482711
Metabolic disorder 863.40 32.08 206 9557 7491 64481478
Dystonia 860.59 32.08 247 9516 18618 64470351
Sedation 835.92 32.08 291 9472 41171 64447798
Personality change 820.54 32.08 202 9561 8391 64480578
Dyskinesia 719.48 32.08 257 9506 39131 64449838
Suicide attempt 627.65 32.08 274 9489 70733 64418236
Inappropriate schedule of product administration 485.10 32.08 249 9514 92037 64396932
Blood glucose increased 409.26 32.08 227 9536 97846 64391123
Underdose 340.85 32.08 133 9630 25696 64463273
Hypoaesthesia oral 286.50 32.08 95 9668 11485 64477484
Akathisia 275.09 32.08 92 9671 11418 64477551
Insurance issue 198.19 32.08 52 9711 2774 64486195
Incorrect route of product administration 179.85 32.08 82 9681 23216 64465753
Adverse drug reaction 111.27 32.08 75 9688 45389 64443580
Emotional poverty 105.98 32.08 24 9739 685 64488284
Swollen tongue 103.52 32.08 65 9698 34889 64454080
Drug ineffective 96.94 32.08 312 9451 839935 63649034
Mania 94.12 32.08 47 9716 16239 64472730
Extrapyramidal disorder 91.60 32.08 49 9714 19503 64469466
Dysgeusia 81.62 32.08 63 9700 46984 64441985
Condition aggravated 75.81 32.08 171 9592 372255 64116714
Suicidal ideation 74.03 32.08 69 9694 66473 64422496
Increased appetite 69.81 32.08 33 9730 10113 64478856
Tardive dyskinesia 60.55 32.08 29 9734 9149 64479820
Weight increased 57.42 32.08 110 9653 213238 64275731
Parkinsonism 56.25 32.08 32 9731 14341 64474628
Antipsychotic drug level below therapeutic 54.33 32.08 15 9748 970 64487999
Therapeutic product effect variable 46.74 32.08 15 9748 1629 64487340
Disinhibition 46.00 32.08 16 9747 2227 64486742
Diarrhoea 44.97 32.08 27 9736 722677 63766292
Neuroleptic malignant syndrome 44.48 32.08 34 9729 24962 64464007
Tooth discolouration 41.06 32.08 12 9751 953 64488016
Obsessive-compulsive disorder 40.45 32.08 18 9745 4800 64484169
Anaemia 40.27 32.08 5 9758 378675 64110294
Agitation 39.10 32.08 57 9706 88310 64400659
Pneumonia 39.05 32.08 18 9745 559558 63929411
Somnolence 38.52 32.08 91 9672 203554 64285415
Cataplexy 33.89 32.08 10 9753 821 64488148
Oral discomfort 33.66 32.08 19 9744 8387 64480582
Pharyngeal hypoaesthesia 33.29 32.08 8 9755 297 64488672
Fatigue 33.02 32.08 39 9724 748691 63740278
Personality change due to a general medical condition 32.96 32.08 7 9756 147 64488822
Drooling 32.65 32.08 16 9747 5303 64483666
Euphoric mood 32.22 32.08 17 9746 6574 64482395

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05AH05 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Diazepines, oxazepines, thiazepines and oxepines
FDA EPC N0000175430 Atypical Antipsychotic
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
CHEBI has role CHEBI:35471 psychotropic drugs
CHEBI has role CHEBI:35530 beta-adrenergic blockers
CHEBI has role CHEBI:37890 alpha-adrenergic receptor blockaders
CHEBI has role CHEBI:48279 serotonin antagonists
CHEBI has role CHEBI:48561 dopaminergic antagonists
CHEBI has role CHEBI:65191 atypical antipsychotic agent

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Mixed bipolar I disorder indication 16506000 DOID:3312
Schizophrenia indication 58214004 DOID:5419
Bipolar affective disorder, current episode manic indication 191618007
Depression Treatment Adjunct off-label use
Suicidal thoughts contraindication 6471006
Weight gain finding contraindication 8943002
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Agranulocytosis contraindication 17182001 DOID:12987
Lowered convulsive threshold contraindication 19260006
Myocardial infarction contraindication 22298006 DOID:5844
Alzheimer's disease contraindication 26929004 DOID:10652
Hypovolemia contraindication 28560003
Orthostatic hypotension contraindication 28651003
Torsades de pointes contraindication 31722008
Dehydration contraindication 34095006
Dysphagia contraindication 40739000
Hypokalemia contraindication 43339004
Bradycardia contraindication 48867003
Hepatic failure contraindication 59927004
Cerebrovascular disease contraindication 62914000 DOID:6713
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Leukopenia contraindication 84828003 DOID:615
Tardive dyskinesia contraindication 102449007
Prolonged QT interval contraindication 111975006
Seizure disorder contraindication 128613002
Hypomagnesemia contraindication 190855004
Cerebrovascular accident contraindication 230690007
Hyperprolactinemia contraindication 237662005 DOID:12700
Transient ischemic attack contraindication 266257000 DOID:224
Esophageal dysmotility contraindication 266434009 DOID:9192
Syncope contraindication 271594007
Neutropenic disorder contraindication 303011007 DOID:1227
Senile dementia with psychosis contraindication 371026009
At risk for aspiration contraindication 371736008
Impaired cognition contraindication 386806002
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Congenital long QT syndrome contraindication 442917000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.13 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 10MG BASE SAPHRIS ALLERGAN N022117 Aug. 13, 2009 RX TABLET SUBLINGUAL 7741358 April 6, 2026 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
EQ 10MG BASE SAPHRIS ALLERGAN N022117 Aug. 13, 2009 RX TABLET SUBLINGUAL 7741358 April 6, 2026 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES (AGES 10 TO ADULT)
EQ 10MG BASE SAPHRIS ALLERGAN N022117 Aug. 13, 2009 RX TABLET SUBLINGUAL 7741358 April 6, 2026 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: AS ADJUNCTIVE TREATMENT TO LITHIUM OR VALPROATE IN ADULTS
EQ 10MG BASE SAPHRIS ALLERGAN N022117 Aug. 13, 2009 RX TABLET SUBLINGUAL 7741358 April 6, 2026 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: MAINTENANCE MONOTHERAPY IN ADULTS
EQ 10MG BASE SAPHRIS ALLERGAN N022117 Aug. 13, 2009 RX TABLET SUBLINGUAL 7741358 April 6, 2026 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS
EQ 2.5MG BASE SAPHRIS ALLERGAN N022117 March 12, 2015 RX TABLET SUBLINGUAL 7741358 April 6, 2026 METHOD OF TREATING MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER IN PEDIATRIC PATIENTS
EQ 2.5MG BASE SAPHRIS ALLERGAN N022117 March 12, 2015 RX TABLET SUBLINGUAL 7741358 April 6, 2026 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES IN PEDIATRIC PATIENTS AGE 10-17
EQ 5MG BASE SAPHRIS ALLERGAN N022117 Aug. 13, 2009 RX TABLET SUBLINGUAL 7741358 April 6, 2026 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
EQ 5MG BASE SAPHRIS ALLERGAN N022117 Aug. 13, 2009 RX TABLET SUBLINGUAL 7741358 April 6, 2026 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES (AGES 10 TO ADULT)
EQ 5MG BASE SAPHRIS ALLERGAN N022117 Aug. 13, 2009 RX TABLET SUBLINGUAL 7741358 April 6, 2026 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: AS ADJUNCTIVE TREATMENT TO LITHIUM OR VALPROATE IN ADULTS
EQ 5MG BASE SAPHRIS ALLERGAN N022117 Aug. 13, 2009 RX TABLET SUBLINGUAL 7741358 April 6, 2026 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: MAINTENANCE MONOTHERAPY IN ADULTS
EQ 5MG BASE SAPHRIS ALLERGAN N022117 Aug. 13, 2009 RX TABLET SUBLINGUAL 7741358 April 6, 2026 USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS
3.8MG/24HR SECUADO HISAMITSU N212268 Oct. 11, 2019 RX SYSTEM TRANSDERMAL 10583121 July 25, 2033 METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH
3.8MG/24HR SECUADO HISAMITSU N212268 Oct. 11, 2019 RX SYSTEM TRANSDERMAL 10814002 July 25, 2033 METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH
5.7MG/24HR SECUADO HISAMITSU N212268 Oct. 11, 2019 RX SYSTEM TRANSDERMAL 10583121 July 25, 2033 METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH
5.7MG/24HR SECUADO HISAMITSU N212268 Oct. 11, 2019 RX SYSTEM TRANSDERMAL 10814002 July 25, 2033 METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH
7.6MG/24HR SECUADO HISAMITSU N212268 Oct. 11, 2019 RX SYSTEM TRANSDERMAL 10583121 July 25, 2033 METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH
7.6MG/24HR SECUADO HISAMITSU N212268 Oct. 11, 2019 RX SYSTEM TRANSDERMAL 10814002 July 25, 2033 METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
3.8MG/24HR SECUADO HISAMITSU N212268 Oct. 11, 2019 RX SYSTEM TRANSDERMAL Oct. 11, 2022 NEW PRODUCT
5.7MG/24HR SECUADO HISAMITSU N212268 Oct. 11, 2019 RX SYSTEM TRANSDERMAL Oct. 11, 2022 NEW PRODUCT
7.6MG/24HR SECUADO HISAMITSU N212268 Oct. 11, 2019 RX SYSTEM TRANSDERMAL Oct. 11, 2022 NEW PRODUCT

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 9.61 WOMBAT-PK CHEMBL
D(2) dopamine receptor GPCR ANTAGONIST Ki 8.75 WOMBAT-PK CHEMBL
Muscarinic acetylcholine receptor M2 GPCR Ki 6.04 PDSP
Histamine H1 receptor GPCR Ki 9 WOMBAT-PK
Beta-1 adrenergic receptor GPCR Ki 5.30 PDSP
Beta-2 adrenergic receptor GPCR Ki 5.30 PDSP
D(1A) dopamine receptor GPCR Ki 8.70 WOMBAT-PK
Alpha-2A adrenergic receptor GPCR Ki 8.19 PDSP
5-hydroxytryptamine receptor 1A GPCR Ki 7.97 WOMBAT-PK
5-hydroxytryptamine receptor 2B GPCR Ki 9.80 WOMBAT-PK
5-hydroxytryptamine receptor 2C GPCR Ki 9.93 WOMBAT-PK
5-hydroxytryptamine receptor 6 GPCR Ki 9.22 WOMBAT-PK
5-hydroxytryptamine receptor 7 GPCR Ki 9.47 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR Ki 8.92 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 8.73 WOMBAT-PK
D(3) dopamine receptor GPCR Ki 9.06 WOMBAT-PK
D(1B) dopamine receptor GPCR Ki 7.64 PDSP
Muscarinic acetylcholine receptor M3 GPCR Ki 5.49 PDSP
Muscarinic acetylcholine receptor M5 GPCR Ki 6.57 PDSP
5-hydroxytryptamine receptor 1B GPCR Ki 8.40 WOMBAT-PK
5-hydroxytryptamine receptor 1D GPCR AGONIST Ki 8.40 IUPHAR
Alpha-2C adrenergic receptor GPCR Ki 7.89 PDSP
Sodium-dependent dopamine transporter Transporter Ki 5.50 PDSP
D(4) dopamine receptor GPCR Ki 8.71 WOMBAT-PK
5-hydroxytryptamine receptor 3A Ion channel Ki 6.35 PDSP
Alpha-1B adrenergic receptor GPCR Ki 8.41 PDSP
5-hydroxytryptamine receptor 5A GPCR Ki 8.60 WOMBAT-PK
Histamine H2 receptor GPCR IC50 8.21 WOMBAT-PK
5-hydroxytryptamine receptor 1E GPCR AGONIST Ki 8 IUPHAR
Muscarinic acetylcholine receptor M1 GPCR Ki 6.11 PDSP

External reference:

IDSource
4029058 VUID
N0000179817 NUI
D02995 KEGG_DRUG
85650-56-2 SECONDARY_CAS_RN
4029058 VANDF
C2000088 UMLSCUI
CHEBI:71253 CHEBI
CHEMBL3187365 ChEMBL_ID
CHEMBL3544974 ChEMBL_ID
DB06216 DRUGBANK_ID
C522667 MESH_SUPPLEMENTAL_RECORD_UI
163091 PUBCHEM_CID
22 IUPHAR_LIGAND_ID
8278 INN_ID
JKZ19V908O UNII
784649 RXNORM
167374 MMSL
26689 MMSL
341671 MMSL
d07473 MMSL
013233 NDDF
013234 NDDF
443374004 SNOMEDCT_US
443375003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
SAPHRIS HUMAN PRESCRIPTION DRUG LABEL 1 0052-0118 TABLET 5 mg SUBLINGUAL NDA 33 sections
SAPHRIS HUMAN PRESCRIPTION DRUG LABEL 1 0052-0119 TABLET 10 mg SUBLINGUAL NDA 33 sections
SAPHRIS HUMAN PRESCRIPTION DRUG LABEL 1 0052-2139 TABLET 5 mg SUBLINGUAL NDA 33 sections
SAPHRIS HUMAN PRESCRIPTION DRUG LABEL 1 0052-2142 TABLET 10 mg SUBLINGUAL NDA 33 sections
SAPHRIS HUMAN PRESCRIPTION DRUG LABEL 1 0456-2402 TABLET 2.50 mg SUBLINGUAL NDA 33 sections
SAPHRIS HUMAN PRESCRIPTION DRUG LABEL 1 0456-2405 TABLET 5 mg SUBLINGUAL NDA 33 sections
SAPHRIS HUMAN PRESCRIPTION DRUG LABEL 1 0456-2410 TABLET 10 mg SUBLINGUAL NDA 33 sections
SAPHRIS HUMAN PRESCRIPTION DRUG LABEL 1 16590-936 TABLET 10 mg SUBLINGUAL NDA 34 sections
ASENAPINE HUMAN PRESCRIPTION DRUG LABEL 1 42794-016 TABLET 5 mg SUBLINGUAL ANDA 21 sections
ASENAPINE HUMAN PRESCRIPTION DRUG LABEL 1 42794-017 TABLET 10 mg SUBLINGUAL ANDA 21 sections
Asenapine Human Prescription Drug Label 1 46708-198 TABLET 5 mg SUBLINGUAL ANDA 29 sections
Asenapine Human Prescription Drug Label 1 46708-199 TABLET 10 mg SUBLINGUAL ANDA 29 sections
Asenapine Human Prescription Drug Label 1 46708-544 TABLET 2.50 mg SUBLINGUAL ANDA 29 sections
Asenapine HUMAN PRESCRIPTION DRUG LABEL 1 51991-358 TABLET 5 mg SUBLINGUAL ANDA 36 sections
Asenapine HUMAN PRESCRIPTION DRUG LABEL 1 51991-359 TABLET 5 mg SUBLINGUAL ANDA 36 sections
Asenapine HUMAN PRESCRIPTION DRUG LABEL 1 51991-360 TABLET 10 mg SUBLINGUAL ANDA 36 sections
Asenapine HUMAN PRESCRIPTION DRUG LABEL 1 51991-361 TABLET 10 mg SUBLINGUAL ANDA 36 sections
Asenapine HUMAN PRESCRIPTION DRUG LABEL 1 51991-928 TABLET 2.50 mg SUBLINGUAL ANDA 36 sections
Asenapine HUMAN PRESCRIPTION DRUG LABEL 1 59762-1091 TABLET 2.50 mg SUBLINGUAL NDA AUTHORIZED GENERIC 33 sections
Asenapine HUMAN PRESCRIPTION DRUG LABEL 1 59762-2012 TABLET 5 mg SUBLINGUAL NDA AUTHORIZED GENERIC 33 sections
Asenapine HUMAN PRESCRIPTION DRUG LABEL 1 59762-2888 TABLET 10 mg SUBLINGUAL NDA AUTHORIZED GENERIC 33 sections
Asenapine Human Prescription Drug Label 1 62332-198 TABLET 5 mg SUBLINGUAL ANDA 29 sections
Asenapine Human Prescription Drug Label 1 62332-199 TABLET 10 mg SUBLINGUAL ANDA 29 sections
Asenapine Human Prescription Drug Label 1 62332-544 TABLET 2.50 mg SUBLINGUAL ANDA 29 sections
Asenapine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 64330-625 TABLET 2.50 1 SUBLINGUAL ANDA 1 sections
SECUADO HUMAN PRESCRIPTION DRUG LABEL 1 68968-0172 FILM, EXTENDED RELEASE 3.80 mg TRANSDERMAL NDA 32 sections
SECUADO HUMAN PRESCRIPTION DRUG LABEL 1 68968-0173 FILM, EXTENDED RELEASE 5.70 mg TRANSDERMAL NDA 32 sections
SECUADO HUMAN PRESCRIPTION DRUG LABEL 1 68968-0174 FILM, EXTENDED RELEASE 7.60 mg TRANSDERMAL NDA 32 sections
Asenapine Human Prescription Drug Label 1 69539-057 TABLET 5 mg SUBLINGUAL ANDA 20 sections
Asenapine Human Prescription Drug Label 1 69539-058 TABLET 5 mg SUBLINGUAL ANDA 20 sections